School of Pharmacy, Sungkyunkwan University, Suwon, Korea.
Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, Korea.
J Diabetes Investig. 2022 May;13(5):830-838. doi: 10.1111/jdi.13719. Epub 2021 Dec 9.
AIMS/INTRODUCTION: To evaluate the relationship between early insulin initiation within a year after type 2 diabetes mellitus diagnosis and the risk of diabetic complications.
We carried out a cohort study using the Korean National Health Insurance Service database. The study participants were newly diagnosed with type 2 diabetes mellitus between 2009 and 2013. After applying propensity score matching (1:1) to the cohort of patients who received two or more oral antidiabetic drugs (OADs) or insulin as the first prescription within 1 year after type 2 diabetes mellitus diagnosis, we computed hazard ratios (HRs) and 95% confidence intervals (CIs) using a Cox proportional hazards regression to compare the risk of diabetes-related microvascular and macrovascular complications and all-cause mortality in insulin versus OAD initiators.
Within the cohort, 52,188 and 1,804 patients received OAD and insulin, respectively. After matching, each group contained 534 patients. Compared with the OAD group, the risk of overall microvascular complications was significantly higher for insulin (HR 1.48, 95% CI 1.28-1.71). No increased risks of overall macrovascular complications (HR 0.90, 95% CI 0.62-1.30) and all-cause mortality were observed (HR 1.06, 95% CI 0.67-1.68).
In the present study, early insulin treatment was not associated with the risk of macrovascular complications and all-cause mortality compared with OAD treatment; however, the risk of microvascular complications was higher in the insulin group.
目的/引言:评估 2 型糖尿病确诊后 1 年内早期开始使用胰岛素与糖尿病并发症风险之间的关系。
我们使用韩国国家健康保险服务数据库进行了一项队列研究。研究对象为 2009 年至 2013 年间新诊断为 2 型糖尿病的患者。在对在 2 型糖尿病确诊后 1 年内接受两种或两种以上口服降糖药(OAD)或胰岛素作为首诊的患者队列进行倾向评分匹配(1:1)后,我们使用 Cox 比例风险回归计算风险比(HR)和 95%置信区间(CI),以比较胰岛素与 OAD 起始治疗者发生糖尿病相关微血管和大血管并发症及全因死亡率的风险。
在该队列中,分别有 52188 例和 1804 例患者接受 OAD 和胰岛素治疗。匹配后,每组各有 534 例患者。与 OAD 组相比,胰岛素组总体微血管并发症风险显著升高(HR 1.48,95%CI 1.28-1.71)。未观察到总体大血管并发症(HR 0.90,95%CI 0.62-1.30)和全因死亡率(HR 1.06,95%CI 0.67-1.68)风险增加。
与 OAD 治疗相比,本研究中早期胰岛素治疗与大血管并发症和全因死亡率风险无关;然而,胰岛素组的微血管并发症风险更高。